Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.42 |
| ▸ | PDE4A | P27815 | 7/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.42 |
| ▸ | WNT3A | P56704 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15874157 | 0.84 | TRPV1 (0.49) | TRPV1MAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL15874156 | 0.84 | TRPV1 (0.49) | TRPV1MAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL9880775 | 0.79 | TRPV1 (0.52) | TRPV1MAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL9880777 | 0.77 | TRPV1 (0.47) | TRPV1PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL9880785 | 0.76 | ALDH1A1 (0.42) | TRPV1MAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL389597 | 0.76 | TRPV1 (0.47) | TRPV1MAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL20260224 | 0.74 | TRPV1 (0.48) | TRPV1MAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL9880759 | 0.73 | TRPV1 (0.52) | TRPV1MAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL15874082 | 0.73 | TRPV1 (0.47) | TRPV1MAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL15886596 | 0.73 | TRPV1 (0.47) | TRPV1MAPTTSHRMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765994-B2 | Ship 1 modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-07-01 | — | — | US | disclosed |
| US-8765994-B2 | Ship 1 modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20120129925-A1 | SHIP 1 MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-05-24 | — | — | US | disclosed |
| US-20080090909-A1 | negative regulator of cell growth factor receptor; pelorol (benzo(a)fluorene) related compounds from marine sponge species; antiinflammatory, antitumor agent, immunostimulant; control gene expression, differentiation, metabolism, phospholipid signaling pathway, signal tansduction | THE UNIVERSITY OF BRITISH COLUMBIA | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090909-A1 | negative regulator of cell growth factor receptor; pelorol (benzo(a)fluorene) related compounds from marine sponge species; antiinflammatory, antitumor agent, immunostimulant; control gene expression, differentiation, metabolism, phospholipid signaling pathway, signal tansduction | STAT1, STING1, IRF3 | TRPV1 958/4885PDE4D 1367/4885PDE4A 1213/4885 |
| US-20120129925-A1 | SHIP 1 MODULATORS | PPP1R10, SACM1L, PPP1R1B | TRPV1 2062/4885PDE4D 446/4885PDE4A 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.